Pulmonary Fibrosis
Conditions
Keywords
Metabolomic, Pulmonary Fibrosis
Brief summary
Pulmonary fibrosis (PF) are a heterogeneous group of interstitial lung diseases who may have a progressive phenotype often associated with loss of lung function, chronic respiratory symptoms, quality of life limitation as well significant morbidity and mortality. The identification of reliable biomarkers able to help in early diagnosis and predict disease progression are crucial for improving patient life. Although many biomarkers have been proposed, there is no consensus on reliable markers for IPF. Alterations in fatty acid (FA) metabolism have drawn increasing attention in the IPF pathogenesis, but there is no consensus on the specific FA changes. Alterations in FA composition have been shown to promote pro-fibrotic traits in epithelial cells, fibroblasts, and myofibroblasts. However, while specific fatty acid (FA) alterations have been identified in the serum of IPF patients, no consensus exists on the exact changes for individual FAs
Interventions
DIAGNOSTIC_TESTFatty acids measurement
Serum analysis for metabolomic biomarker identification
Sponsors
Ceinge - Biotecnologie Avanzate s.c. a r.l.
University of Campania Luigi Vanvitelli
Study design
Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
40 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Confirmed IPF diagnosis based on the 2018 ATS/ERS/JRS/ALAT guidelines \[PMID: 30168753\] or other fibrotising ILDs within the past five years, * Age ≥ 40 years, 3) ability to provide informed consent.
Exclusion criteria
* A current diagnosis of asthma or chronic obstructive pulmonary disease (COPD), 2) an acute PF exacerbation within the past three months. * Use of medications who may alter metabolomic biomarkers, ex. statins.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Fatty acids measurement | six months |
Countries
Italy
Outcome results
None listed